23:05 , Jul 31, 2019 |  BC Extra  |  Clinical News

July 31 Clinical Quick Takes: Novartis' Kisqali shows OS benefit; plus Atlantic and Translate Bio

Kisqali improves survival for postmenopausal breast cancer  Novartis AG (NYSE:NVS; SIX:NOVN) reported interim data showing CDK4/CDK6 inhibitor Kisqali ribociclib plus fulvestrant met the secondary endpoint of significantly improved overall survival in the Phase III MONALEESA-3...
22:38 , Mar 19, 2019 |  BC Extra  |  Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

The Medicines Co. (NASDAQ:MDCO) terminated the employment of Christopher Cox, EVP and chief corporate development officer, effective March 15. Details were not disclosed. Mallinckrodt plc (NYSE:MNK) hired Bryan Reasons as CFO. He will succeed interim...
21:08 , Aug 2, 2018 |  BC Extra  |  Company News

Management tracks: Omeros, EdiGene

Omeros Corp. (NASDAQ:OMER) hired Eckhard Leifke as CMO and VP of clinical development. He was global project head/VP of early project and external opportunities - cardiovascular and metabolism and global head/VP of late-stage development diabetes...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
03:56 , May 12, 2017 |  BC Week In Review  |  Clinical News

Atlantic begins rolling NDA submission for pouchitis candidate alicaforsen

Atlantic Healthcare plc (Saffron Walden, U.K.) began submission of a rolling NDA to FDA for alicaforsen (AP 1007) to treat pouchitis. The antisense inhibitor of intercellular adhesion molecule-1 ( ICAM-1 ; CD54) is in a...
03:55 , May 12, 2017 |  BC Week In Review  |  Clinical News

Atlantic begins rolling NDA submission for pouchitis candidate alicaforsen

Atlantic Healthcare plc (Saffron Walden, U.K.) began submission of a rolling NDA to FDA for alicaforsen (AP 1007) to treat pouchitis. The antisense inhibitor of intercellular adhesion molecule-1 ( ICAM-1 ; CD54) is in a...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
07:00 , Oct 4, 2016 |  BC Extra  |  Company News

Management tracks

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) named Brian McNamara CEO of its Consumer Healthcare division. He replaces Emma Walmsley, who is to succeed CEO Andrew Witty next year. McNamara is head of Europe & Americas in the...
07:00 , Mar 28, 2016 |  BC Week In Review  |  Financial News

Atlantic Healthcare completes venture financing

Atlantic Healthcare plc , Saffron Walden, U.K.   Business: Autoimmune   Date completed: 2016-03-21   Type: Venture financing   Raised: $24 million   Investors: Fullbrook Thorpe Investments; Lloyds Bank; existing investors; individual investors  ...
01:11 , Mar 22, 2016 |  BC Extra  |  Financial News

Atlantic raises $24M venture round

Atlantic Healthcare plc (Cambridge, U.K.) raised $24 million in a venture round from Lorin Johnson and other founders of Salix Pharmaceuticals Inc., Fullbrook Thorpe Investments, LDC and undisclosed existing investors. In 2H17, Atlantic expects results...